Page last updated: 2024-12-07

sch 34826

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sch 34826: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122184
SCHEMBL ID489561
MeSH IDM0158000

Synonyms (10)

Synonym
n-(n-(1-(((2,2-dimethyl-1,3-dioxolan-4-yl) methoxy)carbonyl)-2-phenylethyl)phenylalanine)alanine
sch 34826
beta-alanine, n-(n-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-oxo-1-(phenylmethyl)ethyl)-l-phenylalanyl)-
3-[[(2s)-2-[[1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1-oxo-3-phenylpropan-2-yl]amino]-3-phenylpropanoyl]amino]propanoic acid
105262-04-2
SCHEMBL489561
3-((2s)-2-((1-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-1-oxo-3-phenylpropan-2-yl)amino)-3-phenylpropanamido)propanoic acid
DTXSID00909403
n-[2-({1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1-oxo-3-phenylpropan-2-yl}amino)-1-hydroxy-3-phenylpropylidene]-beta-alanine
AKOS040749449

Research Excerpts

Actions

ExcerptReferenceRelevance
"Sch 34826 prevented the increase in arterial pressure in response to 8% NaCl in SHR-S, but had no effect on blood pressure in 1% NaCl fed SHR-S; plasma ANP levels were increased by 63 and 68% in the 1% and 8% NaCl groups, respectively, in response to Sch 34826."( Effects of acute and chronic blockade of neutral endopeptidase with Sch 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats.
Chen, YF; Esunge, P; Jin, H; Mathews, C; Oparil, S; Wyss, JM; Yang, R, 1992
)
1.24

Dosage Studied

ExcerptRelevanceReference
" bolus dosing with 125I-labelled ANF 99-126."( Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action.
Chiu, PJ; Sybertz, EJ; Vemulapalli, S; Watkins, RW, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.67)18.7374
1990's27 (90.00)18.2507
2000's1 (3.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.13 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.65 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.45%)5.53%
Reviews1 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (90.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]